Organogenesis Inc. of Cambridge, Mass., said it filed anInvestigational Device Exemption (IDE) to start human clinicaltrials with Graftskin, a full-thickness living skin equivalent, forthe treatment of chronic skin wounds resulting from venousdisease. An estimated 900,000 patients in the U.S. suffer fromvenous stasis ulcers each year, according to Thomas M. Tully,president and chief operating officer of Organogenesis.

Graftskin is already in human clinicals for use in dermatologicalsurgery, for non-healing wounds, and also as a temporarywound dressing for burn victims.

(c) 1997 American Health Consultants. All rights reserved.

No Comments